Paradigm Plots Revival Of Butterfly Skin Drug After Amicus Deal
Regains Rights To Topical Whole-Body Treatment
Chiesi-owned Amryt and Krystal Biotech have approved treatments for epidermolysis bullosa but Paradigm CEO Robert Ryan tells Scrip that SD-101, a topical cream he helped develop over 20 years ago, has the potential to be offer a far more extensive and efficacious solution for many more sufferers.
